Skip to main content

For US Healthcare Professionals only

Beyfortus® logo
For OB-GYNS
Dosing & Administration

Sign Up for the Latest Updates

Sanofi is here to help support your patients, their families, and caregivers

For more information regarding Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection, call 1-855-BEYFORTUS (1-855-239-3678) or sign up below to receive the latest updates via email.

By signing up, you will receive the latest updates via email about our webinars, upcoming congresses, pricing promotions, and product- and disease-specific information.

You can opt out of marketing communications at any time.

All fields are required.

Sanofi is here to help support your patients, their families, and caregivers.

For more information regarding Beyfortus® (nirsevimab-alip) Injection, call 1-855-BEYFORTUS (1-855-239-3678) or sign up below to receive the latest updates via email.

All fields are required.

By submitting the following information, you are acknowledging that you understand that the information you provide may be used by Sanofi and their affiliates, and the business service companies working with Sanofi, to provide you with additional communications and to develop products and services, which may include market research.

Sanofi respects your interest in keeping your personal health information private. We will not sell or rent your information to any third parties or outside mailing lists.

You may have certain rights under applicable data privacy laws regarding the personal information that you provide to Sanofi, including the right to access your personal information held by Sanofi. For further information regarding these rights, please reference our Global Privacy Policy.

Call us

For more information about Beyfortus®, contact us at 1-855-BEYFORTUS (1-855-239-3678).

Ordering Beyfortus

For ordering questions or information, contact 1-800-VACCINE (1-800-822-2463).

Medical information

For medical questions or concerns, please contact the medical information team at 1-800-633-1610.

Phone Representative

Reach out to a Sanofi representative to get more information or to order Beyfortus today.

Reach Out to a Sanofi Representative

Important Safety Information

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Indication

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Please see full Prescribing Information.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

Important Safety Information

Indication

MAT-US-2504779-v4.0-06/2026

Back to top
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContactAccessibility Statement
© 2026 Sanofi. All rights reserved.